Note: Descriptions are shown in the official language in which they were submitted.
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
ANTIVIRAL LINEAR POLYMERS
FIELD OF THE INVENTION
This invention relates to antiviral agents, and in particular it relates to polyionic,
especially polyanionic linear polymers which have been found to have signifir~nt antiviral
activity, particularly against human imml-no~eficiency virus (HIV), lcS~ualul ~ syncytial virus
(RSV), human infll~en7A virus A and B, ~atitic B virus (HBV) and other enveloped viruses.
10 BACKGROUND OF THE INVENTION
It has been established that certain sulfonated polysaccharide CO~ )OULIdS have antiviral
activity when screelled against HIV, however these compounds are relatively unstable and
accordingly large amounts of these compounds are required to obtain effective antiviral
15 effects. In addition, many of these colll~vunds, inrlu~ling heparin and dextran sulfate for
example, are potent qn~i~oq~ll-qnt~ and because of this activity they are not particularly suited
for clinical use as antiviral agents.
alional Patent Application No. PCT/AU95/00350 (WO 95/34595) discloses a
20 class of antiviral compounds col~ h~g a del~d~ r such as a polyqmi~3oqrnin~ or polylysine
del~ril~l~,, having a plurality of t~rminql groups, wll~,em at least one of the te ~ groups
has an anionic- or CA~ ;o~ir- COI~ , moiety bonded or linked thereto, particularly a sulfonic
acid-contqining, a carboxylic acid-contAinin or a llin,elllylammonium-co.~ .in~ moiety.
The present invention provides a new class of antiviral agents based on a particular
type of polyionic polymer having a linear Ubackbonen, which have ~ anlivildl
activity against HIV1 and HIV2, RSV, HBV and human inflll~n7A virus A and B. These
compounds are well suited for prophylactic and ~,la~ulic use as antiviral agents in hllTnqn.c.
CA 02262863 1999-01-13
W O 98/03572 PCTIAU97/00446
SUMMARY OF THE INVENTION
According to the present invention, there is provided an antiviral compound
CO~ iSlng a linear non-carbohydrate polymer having a plurality of side chain groups wherein
5 at least one of said side chain groups has an anionic- or cationic-co..~ g moiety bonded
or linked thereto.
Particularly p,efell~,d antiviral compounds of the present invention are linear polymers
having sulfonic acid-cont~ining moieties, carboxylic acid-cont~ining moieties, phosphoric or
10 phosphonic acid~ont~ining moieties, boronic acid-cont~ining moieties, neuraminic or sialic
acid-cont~ining moieties or moieties con~ining neuraminic or sialic acid modified in the 4-
or other position thereof, linked to side chain groups thereof.
The compounds of the invention are referred to herein as polyionic polymers, and this
15 term is used throughout this specification to include not only the polymers per se, but also
their phal... r~,~ti~lly or vel~ ~lily acceptable salts, for exarnple tne ~Ik~lin~o metal or
lin.o earth metal salts such as the sodium, potassium or calcium salts.
DETAILED DESCRIPTION OF THE INVENTION
~ efe.red polyionic polymers in accordance with the prescnt invention are linear
polymers having the general formula I:
25 (~
~- R 1
Wil~.~ill:
R is a non-carbohydrate Illo..olllcr unit fOlll~ing a linear polymer backbone;
30 X is an optional linking group on the side chain groups of .. ~ r units R; and
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
A is an anionic-contAining moiety.
Thus, in accordance with the present invention, the prerelled linear polymers are
polyanionic materials formed by the conjugation of anionic moieties (A) to a linear non-
5 carbohydrate polymer backbone (made up of a plurality of mono,.lc~ units R), optionallythrough linking groups (X). The res~-lt~nt polyanionic linear polymershave a molecular
weight range distribution of repcalillg units to give a desired median range of molecular
weight distribution. Desirably, the median range of molecular weight di~llibulion is from
1,000 to 1,000,000, preferably from 10,000 to 600,000.
The monomer unit R is preferably amine or amide moiety, more preferably an aminoacid moiety. A particularly plcfe.led monomer unit is a lysine moiety. Poly-L-lysines
having various molecular weight ranges are available co,l.ln.,l.;ially from Sigma Ch~rnic~l
Company.
The anionic moiety A can be linked to reactive side chain groups on the linear
polymer bac~olle either directly or via a variety of fim~tion~l linking groups X such as, but
not limited to, esters, amides, ethers, thioethers, amines, ureas, thioureas, c~bA~I~Ates and
call,ulla~s.
The optional linlcing group X may also act as a spacer bel~ell the polymer and the
anionic moiety A, and may consist of an alkyl chain (optionally subs~ Pd or branched), an
alkoxy, polyalkoxy, alkylthio or polyalkylthio chain (optionally subsliLu~.,d), or an alkenyl,
multiple aL~cenyl, aLkynyl or multiple alkynyl chain (optionally substituted). Suitable spacer
25 chains include groups of the formula -(CH2)n-Z-(CH2) n~~ hc~ Z is -CH2-, -CH=CH-, -
C-C-, -O- or -S-, and n is an integer of from 1 to 15.
In accoldallce with the present invention, at least one, and preferably a substantial
number, of the reactive side chain groups on the backbone of the linear polymer has an
30 anionic- or cationic-cont~ining moiety covalently bonded thereto. The side chains of the
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
polymer backbone may te~ ate in amino groups or other functional reactive groups such
as OH, SH, or the like, which subsequently can be reacted with the anionic or cationic
moieties. Where the side chain groups of the polymer backbone are amine groups, the
anionic- or cationic-cont~ining moiety may be linked to the polymer backbone by a variety
5 of functional groups in~ tling amide and thiourea linkages. Pler~,l.ed anionic- or cationic-
cont~ining moieties which may be bonded or linked to the side chain groups of the polymer
backbone include sulfonic acid-cont~ining moieties, carboxylic acid-cont~ining moieties
(mcludmg neurammlc and slallc acld-cont~lnln~ moletles and modlfied lleu~ lmc and slallc
acid-cont~ining moieties), boronic acid-cont~inin~ moieties, phosphoric and phosphonic acid-
10 cont~ining moieties (including esterified phosphoric and phosphonic acid-cont~ining moieties)
and trimethylammonium-cont~ining moieties.
Suitable anionic- and c~tionir~ont~ining moieties which may be bonded or linked to
the amino or other side chain groups of the linear polymers include, by way of example, the
15 following groups (in which n is zero or a positive integer, more particularly n is zero or an
integer of from 1 to 20):
--NH(CHz)nSO3' (CH2)nS03 Ar(so;'n
--CHzcH(so3 )COOH CH~SO3 )CH2COOH --Arx~cH2)nso3- X = O S. NH
(CHz)nNMe3 Ar(NMe3)n Ar(cH2NMe3)n
503Na ~ So3Na J~ --SO3Na /~1 COOH
S S S S
HNJI\ HN)I\ HN~\ HN)I\
¢ I NaO3SJ ~ SO3Na ~ NaO3S b ~ SO3Na
SO3Na SO3Na
S O O
NaO35 HN)I\ HN~l\ HN)~\ q~
NaO3S J~SO3Na ¢~ ¢l ¢l
SO3Na SO3Na SO3~ia
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
~~ ~ OAc
SO3Na COOH
0~ Oq/ NH
Me3 ~ NH2
r~Me3 NMe3
p~=vjlvni2 f~- C. CH2. CHF CF2 R = alkyl. aryl. H Na
ArXP(=O)(OR1)(NR2R3) X= O, CH2, CHF, CF2 Rl= alkyl, aryl, H, Na R2, R3 = alkyl. aryl
Ar[P(=O)(OR)2]n R = alkyl. aryl, H, Na n = 1-3
Ar~B(~H)2ln n = 1-3 Ar~COOH]n n = 1-3
S S S S
'I 11 1~ 11
HN~ HN/\ HN/~ HN/\
~I ' li i ~
\~ W \~ \~PO(ONa)2
Po(oEt)2 PO(OE~)(ONa) PO(ONa)2 po(oNa)2
Sl S
HN /\ HN /\ HN /\
NaOOC ~-~COONa [~
COONa B(ONa)2 B(ONa)2
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
S S S
HN J~ HN J~ HN J~
0~3,0H
po(ONa)Z PO~OEt)~ONa) pO(OEt)2 ~COOH
S S S
HN JJ' ~IN J~ HN J~ HN
S
Po(oNa)2 potoEt~(oNa) PotoEt)2
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
In addition to the above, various neuraminic or sialic acid-cont~inin~ moieties or
modified n~ lall~inic or sialic acid-cont~inin~ moieties may be bonded or linked to the side
chain groups in accordance with this invention. These moieties include the various N- and
O-substitl-tPd derivatives of neuraminic acid, particularly N- and O- acyl derivatives such as
5 N-acetyl, O-acetyl and N-glycolyl derivatives, as well as moieties in which the neuraminic
acid group is modified, particularly by substitution in the 4-position, with an amino, amido,
cyano, azido or g--~ni~ino group.
The polyionic polymers of this invention may be prepared by standard chemical
10 methods which are well known to persons skilled in this art. Suitable methods are described
by way of example in the Examples below.
As previously described, the polyionic polymers of the present invention have been
found to exhibit significant antiviral activity, particularly against enveloped viruses.
15 Accordingly, these polyionic polymers are useful in prophylactic and thelàpculic tre~tmPnt
of viral infections, for example infections by HIV1 and HIV2 and other enveloped viruses
including DNA viruses such as Hep~titic B and RNA viruses inrl--~in~ flaviviruses such as
Hepatitis C, Bovine Viral Diarrhoea Virus and Ja~ se Encephalitis Virus (JEV). The
polyionic polymers of the present invention may also be used in prophylactic or thelalJcu~ic
20 ~ tlllP.lt against Human ~nfl--en7~ Virus A and B, Rhinovi"lses, Corona Viruses, Human
Par~inflllen7~ Virus, Respiratory Syncytial Virus (RSV), Varicella Zoster Virus (VZV),
Human C~ ovirus (CMV), F,rstPin Barr Virus (EBV), Hurnan Papilloma Virus (HPV),
Adenovi~ lses, Herpes Simplex Virus (HSV) type 1 and 2, Measles Virus and Vecie~ r
Stoln~titic Virus (VSV).
~ Thus, in another aspect the present invention provides a })h~ re~ al or vel~lh~aly
composition for prophylactic or therapeutic antiviral 1~ 1 of a human or non-human
anirnal, which col,~ ises a polyionic polymer as broadly dese,il~d above, in ~csoc;~ion with
at least one ~hal"~ e,JIir~lly or vet.,lil~fily acceptable carrier or ~ ent
.
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
The formulation of such compositions is well known to persons skilled in this field.
Suitable ph~rm~relltir~lly acceptable carriers and/or diluents include any and all conventional
solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial
and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such
5 media and agents for pharm~rel~tic~lly active substances is well known in the art, and it is
described, by way of example, in Remington's Phann.q~ellti~nl Sciences, 18th Edition, Mack
Publishing Company, Pennsylvania, USA. Except insofar as any conventional media or agent
is incoll")alible with the active ingredient, use thereof in the pharm~t~eutir~l compositions of
the present invention is contemplated. Supplementary active ingredients can also be
lO incorporated into the compositions.
It is especially advantageous to formulate compositions in dosage unit forrn for ease
of a~lminictration and uniformity of dosage. Dosage unit form as used herein refers to
physically discrete units suited as unitary dosages for the human subjects to be treated; each
15 unit cont~ining a predt~,lllined quantity of active ingredient c~lr~ tf~d to produce the desired
thel~ulic effect in ~ccoci~tit~n with the required pharm~e~ti~l carrier and/or diluent. The
specifications for the novel dosage unit forms of the invention are r~irt~tf~ri by and directly
dependent on (a) the unique characteristics of the active ingredient and the particular
therapeutic effect to be achieved, and (b) the lirnitations hlh~lcl-t in the art of compounding
20 such an active ingredient for the particular tre~tmf ~t.
In another aspect, the present invention provides a method for prophylactic or
thc.~,~ulic tl~ lf ~1 of a viral infection in a human or non-human animal, which comprises
~rlmini~tfring to said human or animal a prophylactic- or thelapculic-antiviral-effective
25 amount of a polyionic polymer as broadly described above.
In yet ~O~ aspect, this invention provides the use of a prophylactic- or lllcla~ltic-
antiviral-effective ~m~unt of a polyionic polymer as broadly desclibed above in the
prophylactic or thclape.llic 1l~ .l of, or in the m~n-lfactllre of a m.~.~lic~mfnt for
30 prophylactic or lhc,~ lic ll~ 1llf~ of a viral infection in a human or non-human animal.
CA 02262863 1999-01-13
W O 98/03S72 PCT/AU97/00446
A variety of ~ dtion routes are available. The particular mode selected willdepend, of course, upon the particular condition being treated and the dosage required for
therapeutic efficacy. The methods of this invention, generally speaking, may be practised
using any mode of .~ .dtion that is m~ic~lly acceptable, mr~ning any mode that
5 produces th~la~cu~ic levels of the active component of the invention without causing clinir~lly
unacceptable adverse effects. Such modes of s~minictration include oral, rectal, topical,
nasal, inh~l~tinn, transdermal or parenteral (e.g. subcutaneous, intram-lcc~ r and
intravenous) routes. Formulations for oral ~rlminictration include discrete units such as
capsules, tablets, lozenges and the like. Other routes include intrathecal ~rlminictration
10 directly into spinal fluid. direct introduction such as by various catheter and balloon
angioplasty devices well known to those of ordinary skill in the art, and intraparenchymal
injection into targeted areas.
The compositions may conveniently be l)lese~ d in unit dosage forrn and may be
15 plc~,al~d by any of the mr-hnrlc well known in the art of pharmacy. Such m~tho-l5 include
the step of b~ illg the active collll>o~ into acsoci~tion with a carrier which cor~.cthut~s one
or more accessoly ingredients. In general, the compositions are ~ Jal~,d by u~uÇolnlly and
intim~tely bringing the active component into association with a liquid carrier, a finely
divided solid carrier, or both. and then, if n~cess~ry, shaping the product.
Compositionc of the present invention suitable for oral ~ àlion may be
plesellled as discl~.te units such as capsules, cachets, tablets or lO7 ~S, each cont~ining a
pre~t~....i.,~-1 amount of the active component, in liposomes or as a ~ ,on in an aqueous
liquor or non-aqueous liquid such as a syrup, an elixir, or an em~l.cion.
~ Compositions suitable for ~al~lll, lal ~ I.àtion conveniently col~lise a sterile
aqueous ~ Jalalion of the active component which is preferably isotollic with the blood of
the recipient. This aqueous pr~ation may be formlll~tecl according to known methods
using those suitable di~ ing or wet~ing agents and s~ e~ agents. The sterile injectable
30 I,l~alalion may also be a sterile inject~l le solution or sn~ o.. in a non-toxic ~alell~lially-
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
- 10-
acceptable diluent or solvent, for example as a solution in polyethylene glycol. Among Lhe
acceptable vehicles and solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed
as a solvent or suspending m~ m For this purpose, any bland fixed oil may be employed
5 including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid find use
in the prepalation of injectables.
The active compound may also be formnl~-Pd for delivery in a system designed to
~(lmini~ter the active component intranasally or by inh~l~tion, for example as a finely
10 dispersed aerosol spray cont~ining the active component.
Other delivery systems can include sl-~t~in~d release delivery systems. Preferred
sustained release delivery systems are those which can provide for release of the active
component of the invention in snst~in~od release pellets or capsules. Many types of snct~in~cl
15 release delivery systems are available. These include, but are not limited to: (a) erosional
systerns in which the active component is contained within a matrix, and (b) diffusional
systems in which the active col,lponellL p~ t s at a controlled rate through a polymer. In
ad.lition, a pump-based hardware delivery system can be used, some of which are adapted for
implantation.
The active component is a 1-..;. .;~ rcd in prophyl~rtir~lly or thf ,Ap,~l~ ;c~lly effective
. A prophyl~tir~lly or Lhc.d~ ;r~lly effective ~mol~nt means that amount nf~ceS.c~ry
at least partly to attain the desired effect, or to delay the onset of, inhibit the progression of,
or halt altogether, the onset or progression of the particular condition being treated. Such
25 amounts will depend, of course, on the particular condition being treated, the severity of the
condition and individual patient parameters including age, physical condition, size, weight
and co~;ul~ l trei~tmPnt~ These factors are well known to those of o~inaly skill in the art
and can be addressed with no more than routine e~l,cl;lnf ~ ;on. It is plefe~lcd generally
that a m~im--m dose be used, that is, the highest safe dose accoldi~lg to sound m.o~ic~l
30 judgement. It will be understood by those of ordinary skill in the art, however, that a lower
CA 02262863 1999-01-13
W O 98/03S72 PCT/AU97/00446
dose or tolerable dose may be ~mini~tered for ml~-lir~l reasons, psychological reasons or for
virtually any other reasons.
Generally, daily oral doses of active component will be from about 0.01 mg/kg per
5 day to 1000 mg/kg per day. Small doses (0.01-1 mg) may be ~ t ~ ed initially, followed
by increasing doses up to about 1000 mg/kg per day. In the event that the response in a
subject is insufficient at such doses, even higher doses (or effective higher doses by a
different, more localised delivery route) may be employed to the extent patient tolerance
permits. Multiple doses per day are contemplated to achieve aypro~liate systemic levels of
I 0 compounds.
The active component according to the invention may also be pltse.lLed for use in the
form of V~t~ .il~ly compositions, which may be prepared, for example, by methods that are
conventional in the art. Examples of such veterinary compositions include those a~pt~ for:
15 (a) oral a~ .aLion. external application, for example drenches (e.g. aqueous or non-
aqueous solutions or s--~pen~ions); tablets or boluses; powdc.~, granules or pellets for
.lle with feed stuffs; pastes for application to the tongue;
(b) pa~ L~ ration for example by subcl~t~n~ous, intl~ cc~ r or intravenous
injection, e.g. as a sterile solution or suspension; or (when appro~iate) by
h~LI~.. ~.-.. -~ry injection where a suspension or solution is introduced into the udder
via the teat;
(c) topical application, e.g. as a cream, o~ nt or spray applied to the skin; or(d) intravaginally, e.g. as a pessary, cream or foam.
Throughout this specificaLion and the claims which follow, unless the context requires
e, the word "co.l,~lise", or variations such as llcollllJlises" or "comprising", will be
understood to imply the inrll-cion of a stated integer or group of ill~gC..S but not the exclusion
of any other integer or group of integers.
Further feaL~s of the present invention will be appdl.,nl from the following Examples
CA 02262863 1999-01-13
W 098/03572 PCT/AU97/00446
which are inrlude~l by way of illustration, not limitation of the invention.
EXAMPLE 1
S Preparation of Sodium 4-Sulfophenylthiourea terminated Polylysines.
A Solid sodiurn 4-sulfophenylisothiocyanate monohydrate (2.55g; lOmmol) was added to
a solution of poly-L-lysine (15-30K) (Sigma Chemical Company) (l.Og) in a mixture
of water (20ml) and N.N-dimethyl-N-allylamine buffer (pH 9.5; 15ml). The resulting
l 0 mixture was heated under nitrogen at 53~ C for 3 hours, when a ninhydrin test was
negative. The cooled mixture was filtered and the filtrate concentrated to give a grey
solid residue. The solid residue was redissolved in water and passed through a column
of Amberlite IR 120(Na) and then concentrated. The crude product was purified by gel
filtration (Sephadex LH20; water) and freeze dried to give sodium 4-sulfophenylthiourea
termin~tec~ poly-L-lysine BRI2995 as a white fluffy solid (1.25g).
B Similarly ~ ,aled were sodiurn 4-sulfophenylthiourea termin~tec~ polylysines of
molecular weight fraction 1 ~K BRI2994,4- 1 SK BRI2967. 150-300K BRI2996.
EXAMPLE 2
Preparation of Sodium 3,6-Disulfonapthylthiourea ter~in~t~l Polylysines.
Solid sodium 3,6-Disulfonapthylisothiocyanate (200mg; 0.51mmol) was added to a
solution of poly-L-lysine (15-30K) (50mg) in a ~r.i~lwe of water (2ml) and N,N-dimethyl-N-
allylamine buffer (pH 9.5; 2ml). The resulting mixture was heated under nitrogen at 53~ C for
3 hours, when a ninhydrin test was negative. The cooled ~ Lule was filtered and the filtrate
concentrated to give a brownish solid residue. The solid residue was redissolved in water and
30 passed through a column of Amberlite IR 120(Na) and then conrf ~ t~d. The crude product
CA 02262863 1999-01-13
W O 98/03S72 PCT/AU97/00446
was purified by gel filtra~ion (Sephadex LH20; water) and freeze dried to give sodium 3,6-
disulfonaphthylthiourea termin~ted poly-L-lysine BRI6047 as a white fluffy solid (87mg).
EXAMPLE 3
Preparation of poly-L-lysyl [(8-oct~n~mi-~o)- 5-~cet~mi~o-3,5~ideoxy-2-thio-D-
glycero-a-D-galacto-2-nonulopyranosidoic acid~n BRI 6150
Poly-L-Lysine / NHCO [CH217-)-- X
~o ~
-~1; = ACI~ COOl-
~C' ' ~S--
L -- n
Methyl [(8-octanoic acid N-hydroxysuccinimide ester) 5-:~etqmido-4,7,8,9-tetra-O-
acetyl-3,5~ideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyranosidlonate was prepared by
20 the following procedure. To a solution of methyl 5-acet~mi~o-4~7~8~9-tetra-o-acetyl-2
acetyl-3,5-dideoxy-2-thio-D-glycero-a-D-galacto-2-nonulopyrqnosonqt~ (A. ~ceg,.wa, J
Nqkqm--ra, and M. Kiso J. Carbohydrate C~h....i~il.y, 5(~ 1-19 1986) (lOOmg.) in dry
dimethylforrn-q-mi-lP (lml.) was added 8-bromooctanoic acid (41mg.) .nd diethylamine
(280mg.) and the solution stirred at 20~ C for 17 hours. Solvent was removed under vacuum
25 and the residue partitioned bc~ ethyl acetate and ice cold 5% hydrochloric acid. The
organic layer was washed with water, dried over sodium s~lphqt~, and evaporated to give a
residue (130mg.). This was dissolved in ethyl acetate (Srnl.) and N-hydroxys~ccinimide
(26mg.) and dicyclohexylcarbo~ mifle (46mg.) were added. The ll~ ule was stirred at 20~
C for 17 hours then the white l,ieci~ilat~ was filtered off. The filtrate was collce.lLIaled and
30 purified by flash chromatography on silica gel eluting with ethyl acetate. I~lacliOl~s cont~ining
CA 02262863 l999-0l-l3
W O 98/03572 PCT/AU97/00446
-14-
product were combined and evaporated to give a white foarn 97mg. 71%
To a solution of poly-L-lysine.HBr MW 150 - 300Kd ( 22mg. ) in dry dimethyl
sulphoxide (lml.) were added di-isopropylethylamine ( l5mg. ) and methyl [(8-octanoic acid
5 N-hydroxysuccinimide ester) 5-~ce~mi~o4,7,8,9-tetra-0-acetyl-3,5-dideoxy-2-thio-D-
glycero-a-D-galacto-2-nonulopyranosid]onate ( 90mg. ). The Illi~lUl'e was stirred under argon
at 20~C for 60 hours then solvent was removed under vacuum. The residue was dissolved in
a freshly ~ ,aled O.5M solution of sodium methoxide in m~h~nol ( 4ml. ) and the mixture
stirred for 48 hours under argon at 20~C. The solvent was evaporated and the residue
l0 dissolved in water (1.5ml.) and stirred for 24 hours . This solution was subjected to size
exclusion chromatography on Sephadex LH20 eluting with water. After Iyophilisation, the
product,poly-L-lysyl [(8-oct~n~mido)-5-~ret~nidQ-3 ,5-dideoxy-2-thio-D-glycero-a-D-galacto-
2-nonulopyranosidoic acid]n was obtained as a white powder 49mg. 94%.
EXAMPLE 4
,al~lion of Sodiwn 3,5-Dicarboxyyl,c,Iylll.iourea t~..,li,.ated Polylysines.
A solution of poly-L-lysine.hydlobroI~Iide (4-lSKO (Sigma ~h~mir~l Company)
(SOmg) in water (2ml) was added to a solution of sodium 3,5-dicarboxyphenyl isothiocyanate
(305mg) in water (3ml) and the pH of the res~ ing solution adjusted to 9 with aqueous
sodium bicalbOI~. The solution was then heated at 53 ~C under nitrogen for 4 hours. The
solution was cooled and filtered, and the filtrate colIcellLlaled to give an off-white solid
25 residue. The crude product was purified by gel filtration (Seph~Irx LH20; water) and freeze
dried to give sodium 3,5-dicarboxyphenylthiourea te~ trd poly-L-lysine as a white fluffy
solid (71mg).
. . .
CA 02262863 1999-01-13
W O 98/03~72 PCT/AU97/00446
EXAMPLE 5
~pa.~ion of Sodium 4-(Phosp~l~nomethyl)phenylthiourea te...,illated Polyly~ cs.
Solid 4-(phosphonomethyl)phenyl isothiocyanate (231mg; 1.0mmol) was added to a
solution of poly-L-lysine.hydrobromide (30-70K) (Sigma Chemir~l Company) (50mg) in a
1:1 rnixture of pyridine/water. The pH of the mixture was adjusted to 9.5 with lM sodium
carbonate and the solution heated overnight at 53 ~C under nitrogen. The mixture was cooled
and filtered, and the filtrate concentrated to give a brown solid residue. The crude product
10 was purifled by gel filtration (Sephadex LH20; water) to give a brown solid (82mg).
EXAMPLE 6
lion of 1-ph~sp~ -oxyphenyl-4thiourea terminated poly-L-lysine.
To a solution of poly-L-lysine hydrobromide (SOmg., Sigma P2636, 30-70 kilodaltons)
in water (1Oml), heated and stirred at 53 DC, was added 4-phosphono-oxyphenyl
isothiocyanate (153mg) and the pH of the mixture adjusted to 9.5-10 with lM sodium
carbonate solution. The mixture was heated and stirred at 53~C for 5 hours and then filtered.
20 The clear solution was purified by gel filtration on Sephadex LH20 eluting with water. The
eluent was lyophilised to give the product as a white foam. 77mg. 94%.
EXAMPLE 7
25 ~ ~dlion of l)e.~ boronic acid te,.. i.. ~ l poly-L-lysine.
-
To a solution of poly-L-lysine hydl obroll~.de (50mg., Sigma P2636, 30-70 kilodaltons)
in DMSO (lOml), under an inert atrnosphere, was added 4-carboxyphenylboronic acid N-
hydro~y~ccin;...ide ester (9Omg) and lM sodium ca,l,o,late solution (2ml) and the mixture
30 stirred at 20~C for 60 hours. Solvent was removed in vacuo and the residue dissolved in
- CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
-16-
water (5ml) and filtered. The clear solution was purified by gel filtration on Sephadex LH20
eluting with water. The eluent was Iyophilised to give the product as a white foam. 50mg.
90%.
EXAMPLE 8
Test for a-,livilal a~ ily.
The results of tests of activity of polyionic linear polymers of this invention against
10 HIV 1, human and murine CMV, HSV 1 and 2 and human influenza A are shown in Tables
1 to 4 respectively. Table 5 shows the antiviral activity of the compound of Exarnple 1
against a broad range of viruses. Tables 6 and 7 show the antiviral activity of the compounds
of Examples 2 and 3, respectively, against RSV, MV and inflllell7~ virus.
Using standard test protocols, antiviral activity was measured as an effective dose
(EC50) of the test compound that protects at least 50~ of the cells used in the test from the
effects of the virus. In addition, because of the re4~ clllellt for safety to the cells by the test
compound, cell cytotoxicity (CCso) is deterrnined as the COllCclllratiOn of the test compound
that kills 50% of uninfected cells. The total antiviral activity can be expressed as the
20 selectivity index (SI), CC50/ECso-
~ CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
TABLE 1 Activity of BRI Linear Polymers against HIV
C~. Fc~ d Virus Conc- ECSO CC50 Antiviral Structure
Strain Index~l
BRI 6047 HIV 1 IIIB l~M 0.002 >3.44 >1720 Poly-l-Lysine(15-30K)
Naphthyl di SO3Na
BRI 2967 HIV 1 IIIB ,uM 0.014 >20.8 ~1480 Poly-l-Lysine(4-15K)
Phenyl-SO3Na
BRI 2994 HIV 1 IIIB ,uM 0.60 >62.5 >1040 Poly-l-Lysine(1~K) Phenyl-
SO3Na
BRI 2995 HIV 1 IIIB ~JM 0.005 >5.7 >1140 Poly-l-Lysinet15-30K)
Phenyl-SO3Na
BRI 2996 HIV 1 IIIB ~JM 0.007 >0.8 ~114 Poly-d-Lysinet150-300K)
Phenyl-SO3Na
St~ Js
AZT HIV 1 1118 ~g/ml 0.0001 1.17 15,775
DS5000 HIV 1 IIIB ~g/ml 0.0263 >250 >9,497
Dextran
Sulfate
TABLE 2 Activity Against Cytomegalovirus (Davis strain) in Cell cultures.
ComrQ~ d EC50 lJ9/ml CCso r~ cicl~;. Cells used
~Ig/ml CCso IJg/ml
BRI 2g95
HCMV CPE Inhibition 2.7 >100 0.1 HFF
HCMV Plaque Reducbon 9.1 >100 0.2 HFF
MCMV Plaque Reductbn 17.7 100 0.5 MEF
HCMV = Human CytoMegaloVirus; MCMV = Murine (Mouse) CytoMegaloVirus.
Tests in Human Embryonic Lung cells (HEL); Human For~sld" FiL,robla~:, (HFF); Mouse Embryonic
Fiblobld~l~ (MEF).
EC50 CPE = Inhibitory concent~d~on to reduce virus CytoPathic Effect on cells by 50%.
CC50 = Cytotoxic concentration required to reduce HEL cell growth by 50%.
CA 02262863 1999-01-13
W O 98/03572 PCT/AU97/00446
-18-
TABLE 3 Activity Against Herpes Simplex 1 & 2 in Cell cultures.
BRI 2995 EC50 ~Jg/ml CCso Ganciclovir
IJg/ml CC50 IJg/ml
HSV-1 CEP inhibition0.88 ~100 0.06 HFF
HSV-1 Plaque Reduction 25.9 ~100 0.3 HFF
HSV-2 CPE Inhibition 1.4 >100 0.2 HFF
HSV-2 Plaque Reduction 13.6 ~100 0.6 HFF
HSV-1 = Human Herpes Simplex Virus-1 (Muco.s~l Herpes).
HSV-2 = Human Herpes Simplex Virus-2 (Genital Herpes).
Tests in Human Foreskin Fibroblasts (HFF).
ECso CPE = Inhibitory concent,alion to reduce virus CytoPathic Effect on cells by 50%.
EC50 Plaque Reduction = Inhibito~ Concent,dli~n to reduce virus plaque by 50%.
CC50 = Cytotoxic concenl~dlion required to reduce cell growth by 50%.
TABLE 4
BRI 6150
Poly-L-Lysine (590K Average (NHCO lCH2l,-)- X
O~OH
\ ~OH
COOH
X = AcHN~/\
HO~
Activity A~ainst Two Strains of Influenza A virus
Compound EC~ g/ml ECso l,glml
Tokyo Strain G70C Strain
BRI 6150 0.03 0.04
CA 02262863 1999-01-13
W O 98/03572 PCTtAU97/00446
- 19-
TABLE 5 Poly-L-Lysine (NHCSNHPhSO3Na)x 26-K-53K
BRI 2995 CPE-inhibition Viral count or CPE-inhibition Viral Count
ARB 95-336 EC50 (CC50)~g/ml Plaque ECso (CCso) ECso (CC50)
Redllction ~glml Sl ~glml Sl
EC50 (CC50)
~g/ml
Virus; Strain
Ribavirin
RSV; Long 10 ('1000) >10010 (100) 10 10 (560) 56 200 (200)
0.3 (30) 100 >0 1 (30)>300 7 (90) 13 1 (40) 40
RSV; A2 0.5 (55) 110 0 1 (>100) >1000 13 (400) 31 2 (>1000) >500
Ganciclovir
CMV; Davis 2.7 (>100) ~379.1 (~100) ~11 0.1 0.2
MCMV 17.7 (>100) ~5.7 0.6
Acyclovir
VZV 93.3 (~100) >1.1 0.5
HSV-1 0.88 (>100) ~125>100(>100) 0 0.06 0.3
HSV-2 1.4 (>100) ~71>100(>100) 0 0.2 0.6
Control drug (?)
FluA; H,N1 2.0 (538)269 2.4 (261)109 6.1 (>100) ~16 5.6 (>100) ~18
~lu-B 6.5 (501)77 6.5 (171)28 3.3 (100) ~30 6.2 (>100) ~16
Concent,dt,ons ~M Zidovudine
HIV-1; IIIB 0.15 (>250) ~1,680 0.00037 (4-38)
11,840
HIV-2; ROD 2.32 (>250) ~108
Viruses: RSV = ResF .dtory Syncytial Virus;
HSV = Herpes Simplex Virus (type 1 = mucosal; type 2 = genital)
CMV = Cytomegalovirus;
VZV = Varicella Zoster Virus;
MCMV = Murine Cyto" ,_9, '- ~;. us
Flu A = Influenza A Virus;
Flu B = Influenza B Virus;
HIV-1 & 2 = Human Immu"od.'i~ _ncy Virus type 1 and 2.
Terrns: CPE = Cytopathic effect of virus on infected cells or when measure of cell toxicity (CCso)
the effect of compound alone on the cell.
... .
CA 02262863 1999-01-13
W O 98/03572 PCTtAU97/00446
-20-
TABLE 6 Poly-L-lysine CONH.CH2CH2NHCSNHlNaphth-3,6-(SO3Na)2]
(37K-75K)
BRI 6047 CPE-inhibition PR=Plaque CPE-inhibition PR = Plaque
ARB-96-222 EC50(ccso) Reduction EC50 (CCsO) Reduction
~Jg/ml NR = Neutral Red llg/mi NR = Neutral Red
Sl cell count Sl cell count
ECso (CC50) EC50 (CC50)
~g/ml ~ug/ml
Sl Sl
Virus; Strain Control Drugs
Ribavirin
RSV; A2 1 (110) 110 NR 7 (90) 13 NR
<1.0 (100) >100 1.0 (40) 40
RSV; A2 VirusYield ECso IJM Virus Yield EC90
EC50 (CC50) sl=cc5olEc9o EC50 CC50 sl=cc50lEc9o
RSV; A2 1.0 (34) 3.0 11 6.0 (71) 6.0 12
MV 18 (55) 3 25 (118) 5
Control Drug (?)
Flu A; H1N1 <1.0 (599)~599 NR 5.6 (>100) ~18 5.0 (>100) ~20
<1.0 (178) ~178
Flu A; H1N1 15 (>100) ~6.7 NR 7.6 (>100) ~16 NR
14 (>100)7.1 5.8 (>100)~13
Flu A; H1N1 3.8 (>100) 26 NR 5.0 (>100) ~20 NR
12 (>100)~8.3 5.4 (>100)~18
Flu A; H1N1 3.2 (>100) ~57 NR 2.2 (>100) ~45 NR
7.2 (>100) ~4 2.8 (>100) ~36
FluA; H1N1 VirusYield ECgo VirusYield ECgo
EC50(CC50) sl=cc50Ec9o EC50CC50 sl=cc50lEc9o
0.53 (140) 0.8 175 4.7 (24) 3.0 8
Flu B 13 (487) 37 NR 4.3 (100) ~23 5.5 (>100)~18
19 (267)14
Flu B Virus Yield ECgo Virus Yield ECgo
EC50 (CC50) sl=cc50lEcso EC50cc5o sl=cc50Ec9o
2.2 (140) 49 2.8 1.7 (24) 1.5 16
- CA 02262863 1999-01-13
W O 98/03~72 PCT/AU97/00446
-21-
TABLE 7 Poly-L-lysine-{NH.CO.(CH2),S-[2-5-acetyl-neuraminic acidl}x (590k)
8RI 6150 CPE-inhibition CPE-inhibition CPE-inhibition CPE-inhibition
ARB-96-227 EC50 (CCso) EC50 (CC50) EC50 (CC50) EC50 (CC50)
~Jg/ml l~g/ml IJg/ml ~Jg/ml
Sl Sl Sl Sl
Virus; Strain Control Dmg
Ribavirin
RSV; A2 <1.0 (>1000)~1000 13.0 (400) 31
RSV; A2 <1.0 (>1000)~1000 2.0 (>1000) ~500
Flu B <1 (>720) >720 NR NR
c1 >1000 ~1000 1.8(>100) >56
RSV; A2 Viral Yield ECgo ViralYield ECgo
ECso (CC50) sl=cC50lEc9o EC50 (CC50) sl=cC50lEc9o
3.0 (>1000) 2.0 ~500 6.0 (71) 6.0 12
